GlassScriptPhysician profile
Ramon Garza
NPI 1619925831
$851.16
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.88 · 2021: $32.69 · 2022: $441 · 2023: $163 · 2024: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $366.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $358.08 | 2022-2023 | Freestyle Libre 3 |
| Abbvie INC. | $159.37 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.06 | 2022-2023 | Synjardy, Jardiance |
| Merck Sharp & Dohme LLC | $38.96 | 2021-2022 | |
| Medtronic, INC. | $34.16 | 2022 | |
| Novo Nordisk INC | $30.77 | 2019-2022 | |
| Tandem Diabetes Care, INC. | $25.82 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Acera Surgical, INC. | $23.97 | 2023 | Restrata Wound Matrix |
| Tactile Systems Technology INC | $21.95 | 2024 | Flexitouch Plus, Entre Plus |
| Tela Bio, INC. | $21.40 | 2024 | Ovitex 2s |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramon Garza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.